A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can generate deep and durable responses in extramedullary multiple ...

Patients with plasmacytomas that are noncontiguous with bone marrow (true extramedullary myeloma) are at high risk for disease progression or relapse. Phase 1 of the RedirecTT-1 study showed promising ...

ROCHESTER, Minn. — A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can generate deep and durable responses in ...

Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in ...

Please provide your email address to receive an email when new articles are posted on . In this interview Shahzad Raza, MD, discusses a study on the treatment of patients with extramedullary myeloma, ...

A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency. Curability of multiple myeloma (MM) based on relative survival rate (RSR) ...

ORLANDO -- For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination of talquetamab (Talvey) and teclistamab (Tecvayli) achieved high response ...

Talquetamab appears to produce the highest overall response rates vs other types of bispecific antibody monotherapy among patients with relapsed/refractory multiple myeloma in a systematic review.